Last $0.0035 USD
Change Today 0.00 / 0.00%
Volume 0.0
TRAB On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 06/30/14 All times are local (Market data is delayed by at least 15 minutes).

therabiogen inc (TRAB) Snapshot

Open
$0.0035
Previous Close
$0.0035
Day High
$0.0035
Day Low
$0.0035
52 Week High
04/9/14 - $0.01
52 Week Low
12/19/13 - $0.0008
Market Cap
252.6K
Average Volume 10 Days
13.2K
EPS TTM
$-0.39
Shares Outstanding
72.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for THERABIOGEN INC (TRAB)

Related News

No related news articles were found.

therabiogen inc (TRAB) Related Businessweek News

No Related Businessweek News Found

therabiogen inc (TRAB) Details

TheraBiogen, Inc. develops, manufactures, markets, and sells over-the-counter homeopathic pharmaceutical products that aid in the relief of various symptoms and illnesses. The company’s products include THERA MAX cold and flu relief, THERA MAX allergy relief, and THERA MAX migraine relief products. It is also developing THERA MAX sore throat relief product. The company sells its products to the pharmaceutical retail chain or grocery retail chain through third parties primarily in North America. TheraBiogen, Inc. was founded in 2000 and is based in Freehold, New Jersey.

therabiogen inc (TRAB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

therabiogen inc (TRAB) Key Developments

TheraBiogen To Be Deleted From OTCBB

TheraBiogen Inc.’s common stock will be deleted from OTC Bulletin Board (OTCBB) effective November 20, 2012, on account of failure to comply with rule NASD 6530. The company will be added to NBB.

TheraBiogen Inc. Announces Resignation of Kelly T. Hickel, as Chairman and Chief Executive Officer

TheraBiogen Inc. announced that, effective October 12, 2012, Kelly T. Hickel, Chairman and CEO, resigned as an officer, director and employee of the company for personal reasons.

TheraBiogen Inc. Announces Resignation of Thomas E. Kelly as Director; Lender Declares Therabiogen Inc. in Default to Pay $250,000 Line of Credit

TheraBiogen Inc. is a party to a financing agreement with its principal lender, which holds a first priority security interest in its assets. Due to the financial circumstances, the company has been unable to pay the lender amounts due under a $250,000 line of credit used for the financing of inventory purchases, plus certain related fees, as well as accrued interest on the line of credit, and the lender has declared the company in default of these obligations. The company also has been unable to secure alternate financing to retire the amounts due. The company is now advised that the lender has initiated steps to foreclose on its security interest in the assets and that a foreclosure sale will be held on November 8, 2012. Unless this foreclosure and sale in postponed or alternative arrangements can be made, the company will be without any operating assets as a result, and will no longer be able to engage in any business activity or pay debts. While the Board of Directors has discussed the possibility of filing a Chapter 11 bankruptcy proceeding, or lack of any cash or other resources needed to retain a bankruptcy attorney to commence and maintain such an action has precluded this option. Effective October 25, 2012, one of the Directors, Thomas E. Kelly resigned from his position as Director for personal reasons.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRAB:US $0.00 USD 0.00

TRAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TRAB.
View Industry Companies
 

Industry Analysis

TRAB

Industry Average

Valuation TRAB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERABIOGEN INC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.